Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy

• Published in: Pharmacogenomics Vol. 13; no. 8; p. 955
• Main Authors: O'Connor, Shanna K, Ferreri, Stefanie P, Michaels, Natasha M, Greco, Angelo J, Viera, Anthony J, Faruki, Hawazin, McLeod, Howard L, Roederer, Mary W
• Format: Journal Article
• Language: English
• Published: England 01-06-2012
• Subjects: Aryl Hydrocarbon Hydroxylases - genetics; Cytochrome P-450 CYP2C19; Drug Prescriptions; Genetic Testing; Humans; Pharmacies; Pharmacists; Pharmacogenetics - methods
• ISSN: 1744-8042
• DOI: 10.2217/pgs.12.67

To describe the exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. An institutional review board-approved protocol for a clopidogrel pharmacogenetic program in a community pharmacy was developed to address feasibility and evaluate the pilot program.
Subjects taking clopidogrel are asked to participate at the point of medication dispensing. A pharmacist schedules an appointment with subjects to discuss the study and collects a buccal swab sample for CYP2C19 testing. When the results are available, the pharmacist consults with the subject's prescriber regarding test result interpretation and associated recommendations, and schedules a second appointment with the participant to discuss results and review any physician-approved therapeutic changes. The intervention-associated consultation is then billed to the subject's insurance.
Subject enrollment has begun.
Community pharmacists may be valuable partners in pharmacogenetics.